RESUMO
BACKGROUND: The hepatitis C virus (HCV) mutates within human leucocyte antigen (HLA) class I restricted immunodominant epitopes of the non-structural (NS) 3/4A protease to escape cytotoxic T lymphocyte (CTL) recognition and promote viral persistence. However, variability is not unlimited, and sometimes almost absent, and factors that restrict viral variability have not been defined experimentally. AIMS: We wished to explore whether the variability of the immunodominant CTL epitope at residues 1073-1081 of the NS3 protease was limited by viral fitness. PATIENTS: Venous blood was obtained from six patients (four HLA-A2+) with chronic HCV infection and from one HLA-A2+ patient with acute HCV infection. METHODS: NS3/4A genes were amplified from serum, cloned in a eukaryotic expression plasmid, sequenced, and expressed. CTL recognition of naturally occurring and artificially introduced escape mutations in HLA-A2-restricted NS3 epitopes were determined using CTLs from human blood and genetically immunised HLA-A2-transgenic mice. HCV replicons were used to test the effect of escape mutations on HCV protease activity and RNA replication. RESULTS: Sequence analysis of NS3/4A confirmed low genetic variability. The major viral species had functional proteases with 1073-1081 epitopes that were generally recognised by cross reactive human and murine HLA-A2 restricted CTLs. Introduction of mutations at five positions of the 1073-1081 epitope prevented CTL recognition but three of these reduced protease activity and RNA replication. CONCLUSIONS: Viral fitness can indeed limit the variability of HCV within immunological epitopes. This helps to explain why certain immunological escape variants never appear as a major viral species in infected humans.
Assuntos
Hepacivirus/genética , Hepatite C/imunologia , Tolerância Imunológica , Proteínas não Estruturais Virais/genética , Doença Aguda , Adulto , Animais , Citotoxicidade Imunológica , Epitopos de Linfócito T/imunologia , Feminino , Genes Virais , Variação Genética/imunologia , Antígeno HLA-A2/metabolismo , Hepacivirus/imunologia , Hepatite C/virologia , Hepatite C Crônica/imunologia , Hepatite C Crônica/virologia , Humanos , Epitopos Imunodominantes/genética , Epitopos Imunodominantes/imunologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Pessoa de Meia-Idade , Mutação , Fragmentos de Peptídeos/imunologia , RNA Viral/genética , Linfócitos T Citotóxicos/imunologia , Proteínas não Estruturais Virais/imunologia , Replicação Viral/genética , Replicação Viral/imunologiaRESUMO
We have recently shown that the NS3-based genetic immunogens should contain also hepatitis C virus (HCV) nonstructural (NS) 4A to utilize fully the immunogenicity of NS3. The next step was to try to enhance immunogenicity by modifying translation or mRNA synthesis. To enhance translation efficiency, a synthetic NS3/4A-based DNA (coNS3/4A-DNA) vaccine was generated in which the codon usage was optimized (co) for human cells. In a second approach, expression of the wild-type (wt) NS3/4A gene was enhanced by mRNA amplification using the Semliki forest virus (SFV) replicon (wtNS3/4A-SFV). Transient tranfections of human HepG2 cells showed that the coNS3/4A gene gave 11-fold higher levels of NS3 as compared to the wtNS3/4A gene when using the CMV promoter. We have previously shown that the presence of NS4A enhances the expression by SFV. Both codon optimization and mRNA amplification resulted in an improved immunogenicity as evidenced by higher levels of NS3-specific antibodies. This improved immunogenicity also resulted in a more rapid priming of cytotoxic T lymphocytes (CTLs). Since HCV is a noncytolytic virus, the functionality of the primed CTL responses was evaluated by an in vivo challenge with NS3/4A-expressing syngeneic tumor cells. The priming of a tumor protective immunity required an endogenous production of the immunogen and CD8+ CTLs, but was independent of B and CD4+ T cells. This model confirmed the more rapid in vivo activation of an NS3/4A-specific tumor-inhibiting immunity by codon optimization and mRNA amplification. Finally, therapeutic vaccination with the coNS3/4A gene using gene gun 6-12 days after injection of tumors significantly reduced the tumor growth in vivo. Codon optimization and mRNA amplification effectively enhances the overall immunogenicity of NS3/4A. Thus, either, or both, of these approaches should be utilized in an NS3/4A-based HCV genetic vaccine.
Assuntos
Códon , Hepacivirus/genética , Hepatite C/prevenção & controle , RNA Mensageiro/genética , Vacinas de DNA/genética , Vacinas contra Hepatite Viral/genética , Animais , Anticorpos Antivirais/sangue , Cricetinae , Feminino , Citometria de Fluxo , Amplificação de Genes , Engenharia Genética/métodos , Hepacivirus/imunologia , Hepatite C/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Modelos Animais , Linfócitos T Citotóxicos/imunologia , Vacinas de DNA/imunologia , Vacinas contra Hepatite Viral/imunologiaRESUMO
The hepatitis C virus (HCV) protease and helicase encompasses the nonstructural (NS) 3 protein and the cofactor NS4A, which targets the NS3/4A-complex to intracellular membranes. We here evaluate the importance of NS4A in NS3-based genetic immunogens. A full-length genotype 1 NS3/4A gene was cloned into a eucaryotic expression vector in the form of NS3/4A and NS3 alone. Transient transfections revealed that the inclusion of NS4A increased the expression levels of NS3. Subsequently, immunization with the NS3/4A gene primed 10- to 100-fold higher levels of NS3-specific antibodies as compared to immunization with the NS3 gene. Humoral responses primed by the NS3/4A gene had a higher IgG2a/IgG1 ratio (>20) as compared to the NS3 gene (3.0), suggesting a T helper 1-skewed response. Low dose i.m. (10 microg) immunization with the NS3/4A gene inhibited the growth of NS3/4A-expressing tumor cells in vivo, whereas the NS3 gene alone or NS3 protein did not. We then evaluated the efficiency of the NS3/4A gene administered by the gene gun, at the same doses used for humans, in priming cytotoxic T lymphocyte (CTL) responses. Three to four 4 microg doses of the NS3/4A gene primed CTL at a precursor frequency of 2-4%, which inhibited the growth of NS3/4A-expressing tumor cells in vivo. Thus, NS4A enhances the expression levels and immunogenicity of NS3, and an NS3/4A gene delivered transdermally could be a therapeutic vaccine candidate.
Assuntos
Terapia Genética/métodos , Hepacivirus/genética , Mieloma Múltiplo/terapia , Vacinas de DNA/administração & dosagem , Animais , Biolística , Imuno-Histoquímica , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Mieloma Múltiplo/imunologia , Mieloma Múltiplo/virologia , Estatísticas não Paramétricas , Linfócitos T Citotóxicos/imunologia , Células Th1/imunologia , Proteínas não Estruturais Virais/genéticaRESUMO
The development of DNA vaccination to mucosal surfaces has continued apace over the last 2 years, with the investigation of several novel delivery vehicles. There have been advances in the understanding of the basic immunological mechanisms behind the induction of immune responses by plasmid DNA. The mechanistic insights are paving the way for the design of a second generation of mucosally delivered DNA vaccines. This article reviews the recent progress in the field of microparticle, cationic lipid and bacterial delivery systems. All these mechanisms afford some protection from environmental degradation and facilitate DNA uptake. These methods have been compared with respect to transfection efficiency, ability to elicit a full range of immune responses and their relative safety for in vivo applications.
Assuntos
Imunidade nas Mucosas , Vacinas de DNA/administração & dosagem , Animais , Bactérias/genética , Biolística , Sistemas de Liberação de Medicamentos , Vetores Genéticos , Humanos , Lipídeos , Microesferas , Vacinas de DNA/genética , Vacinas de DNA/imunologiaRESUMO
The nasal mucosa provides a simple, non-invasive route to deliver DNA encoding the gene of interest to stimulate mucosal and systemic immune responses. However, unlike the intradermal or intramuscular routes for plasmid DNA (pDNA) delivery, immune responsiveness to antigen exposure at the respiratory mucosa is tightly regulated, consistent with the balance between active immunity and non-responsiveness to pathogenic or inert environmental antigens. We have characterised the antigen presenting cell types, their distribution and activation status following nasal vaccination with pDNA-cytofectin complexes encoding model antigens. We demonstrate that nasal immunisation is associated with expression of the encoded protein in a small population of dendritic cells and macrophages at the site of pDNA delivery, in the draining lymph nodes (LN) and in the spleen. Antigen expression by nasal dendritic cells was associated with up-regulation of surface MHC class II and CD86 expression and functional activation of T-lymphocytes. The results highlight the potential of intranasal vaccination with pDNA, provided the activation / costimulatory requirements for an active immune response are achieved.
Assuntos
Imunidade nas Mucosas , Vacinas de DNA/administração & dosagem , Administração Intranasal , Fosfatase Alcalina/genética , Fosfatase Alcalina/imunologia , Fosfatase Alcalina/metabolismo , Animais , Antígenos/genética , Células Dendríticas/imunologia , Feminino , Expressão Gênica , Proteínas de Fluorescência Verde , Luciferases/genética , Luciferases/metabolismo , Proteínas Luminescentes/genética , Proteínas Luminescentes/metabolismo , Ativação Linfocitária , Macrófagos/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Mucosa Nasal/imunologia , Plasmídeos/administração & dosagem , Plasmídeos/genética , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/metabolismo , Linfócitos T/imunologia , Vacinas de DNA/genética , Vacinas de DNA/imunologiaRESUMO
The development of vaccines against pathogens transmitted across the genito-rectal mucosa that effectively stimulate both secretory IgA Abs and cytotoxic T lymphocytes in the genital tract and CTL in the draining lymph nodes (LN) has proven a major challenge. Here we report a novel, noninvasive approach of genetic vaccination via the intranasal route. Such vaccination elicits immune responses in the genital and rectal mucosa, draining LNs, and central lymphoid system. Intranasal immunization with plasmid DNA-lipid complexes encoding the model Ag firefly luciferase resulted in dissemination of the DNA and the encoded transcript throughout the respiratory and gastrointestinal tracts, draining LNs, and spleen. Complexing the plasmid DNA with the lipid DMRIE/DOPE enhanced expression of the encoded protein in the respiratory tract, increased specific secretory IgA Ab in the vaginal and rectal tracts, and increased the circulating levels of specific IgA and IgG. In addition, intranasal DNA immunization resulted in generation of Ag-specific CTL that were localized in the genital and cervical LNs and spleen. These results suggest that intranasal immunization with plasmid DNA-lipid complexes may represent a generic immunization strategy against pathogens transmitted across the genito-rectal and other mucosal surfaces.
Assuntos
Genitália Feminina/imunologia , Imunidade nas Mucosas/imunologia , Fosfatidiletanolaminas/imunologia , Plasmídeos/imunologia , Reto/imunologia , Vacinas de DNA/imunologia , Administração Intranasal , Animais , Líquidos Corporais/enzimologia , Líquidos Corporais/imunologia , Citotoxicidade Imunológica , Epitélio/enzimologia , Epitélio/imunologia , Feminino , Imunoglobulina A Secretora/biossíntese , Imunoglobulina G/biossíntese , Luciferases/biossíntese , Luciferases/genética , Luciferases/imunologia , Linfonodos/citologia , Linfonodos/enzimologia , Linfonodos/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Mucosa Nasal/enzimologia , Mucosa Nasal/imunologia , Fosfatidiletanolaminas/administração & dosagem , Plasmídeos/metabolismo , RNA Mensageiro/metabolismo , Baço/citologia , Baço/enzimologia , Baço/imunologia , Linfócitos T Citotóxicos/enzimologia , Linfócitos T Citotóxicos/imunologia , Fatores de Tempo , Vacinas de DNA/administração & dosagem , Vagina/enzimologia , Vagina/imunologiaRESUMO
The mucosal surfaces represent the primary site for transmission of several viruses including HIV. To prevent mucosal transmission and dissemination to the regional lymph nodes, an effective HIV vaccine may need to stimulate immune responses at the genital and rectal mucosa. Optimal induction of mucosal immunity in general requires targeting antigens to the specialized antigen presenting cells of mucosal associated lymphoid tissues. The nasal mucosa may provide a simple, non-invasive route to deliver DNA encoding the introduced gene to stimulate mucosal immunity. As a first step to evaluate the feasibility of this approach, we have investigated as a model system, systemic and mucosal immune responses elicited to firefly luciferase generated by DNA immunization. Incorporating DNA into liposomes with cationic lipids enhanced luciferase expression in nasal tissue, and was associated with induction of a humoral response in serum and vaginal fluids and also a proliferative and cytotoxic T lymphocyte response in the spleen and iliac lymph nodes draining the genital and rectal mucosa.
Assuntos
Vacinas contra a AIDS/administração & dosagem , Anticorpos Anti-HIV/biossíntese , HIV-1/imunologia , Imunidade nas Mucosas , Lipossomos , Vacinas de DNA/administração & dosagem , Vacinas contra a AIDS/imunologia , Administração Intranasal , Animais , DNA Viral/imunologia , Ensaio de Imunoadsorção Enzimática , Feminino , HIV-1/genética , Lipídeos , Camundongos , Fosfatidiletanolaminas , Compostos de Amônio Quaternário , Linfócitos T/imunologia , Linfócitos T Citotóxicos/imunologia , Vacinas de DNA/imunologiaAssuntos
Imunoglobulina A/biossíntese , Luciferases/biossíntese , Luciferases/imunologia , Linfócitos T Citotóxicos/imunologia , Vacinas de DNA/administração & dosagem , Administração Intranasal , Animais , Formação de Anticorpos , Portadores de Fármacos , Feminino , Genes Reporter , Imunidade Celular , Imunização/métodos , Lipossomos , Camundongos , Camundongos Endogâmicos BALB C , Mucosa Nasal , PlasmídeosRESUMO
A method for the routine profiling of illicit heroin samples received in casework has been developed which depends on simple and straightforward sample pretreatment, followed by gas chromatography on a capillary column using flame-ionization detection. The factors affecting the choice of each aspect of the procedure are discussed, as are the statistical data for sampling and the chromatography. Components of illicit heroin derived from opium and other adulterants have been identified. The significance of data from samples examined in 1986 is discussed.
Assuntos
Medicina Legal , Heroína/análise , Cromatografia Gasosa , Contaminação de MedicamentosRESUMO
The details of a fatal self-poisoning with the anti-arrhythmic drug tocainide are described. The authors are unaware of another such case. The physiological and toxicological results are post mortem are presented and discussed, with emphasis on the method of analysis of the drug in the body fluids and tissues. Stomach content was analysed by direct solvent extraction followed by ultraviolet spectrophotometry and thin-layer chromatography. Blood, urine and liver concentrations were obtained by high-pressure liquid chromatography, blood and liver samples being extracted under basic conditions and urine analysed directly. Two methods are compared for the liver analysis; an alkaline extraction of an enzymic digestion yielded lower levels of drug than did a mechanical maceration followed by alkaline extraction and 'salting out'. The latter is an adaptation of the method used for analysis of blood. Details of therapeutic and toxic blood/plasma concentrations are taken from the literature and compared with the analytical data, leading to the conclusion that the only logical cause of death was tocainide poisoning.